Balyasny Asset Management
CABA icon

Balyasny Asset Management’s Cabaletta Bio CABA Stock Holding History

Balyasny Asset Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,154
Closed -$30K – 3038
2026
Q1 		$30K Sell
11,154
-40,398
-78% -$112K ﹤0.01% 2787
2025
Q4 		$113K Buy
+51,552
New +$128K ﹤0.01% 2946
2024
Q4 		– Sell
-98,673
Closed -$466K – 2778
2024
Q3 		$466K Buy
98,673
+41,845
+74% +$242K ﹤0.01% 2286
2024
Q2 		$425K Buy
56,828
+41,865
+280% +$513K ﹤0.01% 2120
2024
Q1 		$255K Buy
+14,963
New +$321K ﹤0.01% 2319

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Balyasny Asset Management's CABA Position: Q2 2026 in Review

Balyasny Asset Management sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 11,154 shares — an estimated $30K sold.

Balyasny Asset Management first reported a position in CABA in Q1 2024 and held it in 5 quarters. The position peaked at $466K in Q3 2024. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Balyasny Asset Management reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 11,154 Cabaletta Bio shares in Q2 2026, an estimated $30K.
  • Balyasny Asset Management first reported a position in Cabaletta Bio in Q1 2024 and held it in 5 quarters.
  • Balyasny Asset Management's Cabaletta Bio position peaked at $466K in Q3 2024.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.